Filing Flows › Health Care › Editas Medicine (EDIT)
Editas Medicine (EDIT) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 5, 2026 · Editas Medicine (EDIT) Q2 2026 earnings results →
Q2 2026 Revenue up 232% year over year to $11.9M · 153¢ of every $1 of revenue lost · operating margin -156.0%
Editas Medicine made $11.9M in Q2 2026 (+232% Y/Y). Operating margin -156.0%, net loss $18.2M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 5, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $11.9M in Q2 2026, up 232% year over year and up 320% from the previous quarter.
Operating costs exceeded revenue by $18.6M, an operating margin of -156.0%. Total costs fell 45% while revenue rose 232%. The quarter ended with a net loss of $18.2M, narrower than the previous quarter's $25.0M loss.
Operating cash flow was −$29.6M. Non-cash charges added back $416K of depreciation and $2.2M of share-based compensation. Working capital and other items used $13.9M. Capital expenditures of $106K exceeded it, leaving free cash flow of −$29.7M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 5, 2026 | $11.9M | +232% | -156.0% | −$18.2M | −$29.6M |
| Q1 2026 | 10-Q | May 5, 2026 | $2.8M | -39% | -883.2% | −$25.0M | −$23.1M |
| Q4 2025 | 10-K | Mar 9, 2026 | $24.7M | -19% | -31.3% | −$5.6M | −$36.4M |
| Q3 2025 | 10-Q | Nov 10, 2025 | $7.5M | 124× | -325.4% | −$25.1M | −$30.8M |
| Q2 2025 | 10-Q | Aug 12, 2025 | $3.6M | +598% | n/m | −$53.2M | −$50.2M |
| Q1 2025 | 10-Q | May 12, 2025 | $4.7M | +310% | n/m | −$76.1M | −$47.8M |
| Q4 2024 | 10-K | Mar 5, 2025 | $30.6M | -49% | -152.2% | −$45.4M | −$50.8M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Editas Medicine
We are a pioneering gene editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The promise of genomic medicines is supported by the advancing knowledge of the human genome and by harnessing the progress in technologies for cell therapy, gene therapy, and, most recently, gene editing. We believe this progress sets the stage for us to create medicines with the potential to have a durable benefit for patients. Our core capability in gene editing uses the technology known as CRISPR (clustered, regularly interspaced, short palindromic repeats) to allow us to create molecules that efficiently and specifically edit DNA. Our mission is to translate the promise of gene editing into a broad class of differentiated, transformational medicines for previously untreatable diseases.
In its own words, from its 10-K, filed Mar 9, 2026.
Editas Medicine against its Biological Products, (No Diagnostic Substances) peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +232% against the peers' median +29%. Operating margin: -156.0% against the peers' median 35.8%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| EDIT Editas Medicine | Q2 2026 | $11.9M | +232% | -156.0% |
| AMGN Amgen | Q3 2026 | $10.4B | +8% | 35.8% |
| GILD Gilead Sciences | Q3 2026 | $8.3B | +7% | 41.7% |
| BIIB Biogen | Q3 2026 | $2.8B | +11% | -0.3% |
| MRNA Moderna | Q3 2026 | $1.3B | +29% | 9.9% |
| NBIX Neurocrine Biosciences | Q3 2026 | $1.1B | +41% | 29.5% |
| EXEL Exelixis | Q3 2026 | $659M | +10% | 40.8% |
| HALO Halozyme Therapeutics | Q3 2026 | $493M | +39% | 59.8% |
| MGTX MeiraGTx Holdings | Q2 2026 | $321M | 87× | 76.0% |
Source: Editas Medicine 10-Q on SEC EDGAR · CIK 1650664 · Biological Products, (No Diagnostic Substances)
13F: who owns EDIT and who is buying
More on EDIT
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results